Synairgen plc (SYGGF)
OTC PINK OTC PINK Primary Summary
Synairgen shares stay tradeable post-delisting, as top investor waives restrictions
Synairgen PLC (AIM:SNG, OTC:SYGGF), a biotech company developing an experimental inhaled treatment for respiratory infections, says its shares will remain freely tradeable - even after its recent move to go private. The company, best known for its investigational drug SNG001, updated investors following a vote last week to delist from AIM and become a private limited company.
Synairgen becomes the latest company to eye the AIM exit door
Synairgen PLC (AIM:SNG, OTC:SYGGF) is set to become the latest in a growing wave of smaller companies leaving London's AIM market after struggling to lock down fresh investment. The biotech firm, which has been developing an inhaled treatment for respiratory infections, confirmed plans to cancel its AIM listing and go private after failing to meet fundraising targets.
Synairgen CEO on funding phase 2 trial for SNG001 - ICYMI
Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talked with Proactive about the company's recent fundraising efforts to support a phase II clinical trial. The study aims to test SNG001, a broad-spectrum inhaled antiviral, in critically ill patients requiring mechanical ventilation due to respiratory viruses.
Synairgen plc (SYGGF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Synairgen plc ever had a stock split?
Synairgen plc Profile
| Biotechnology Industry | Healthcare Sector | Joseph Tregonning Colliver CEO | OTC PINK Exchange | GB00B0381Z20 ISIN |
| GB Country | 34 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Synairgen plc is a biotechnological company focusing on the discovery and development of pharmaceutical solutions aimed at treating respiratory diseases. With a foundation year of 2004, the company is based in Southampton, the United Kingdom. It has marked its presence in the field by focusing on creating treatments for a range of respiratory conditions, leveraging its expertise in the area of inhaled therapies. A notable aspect of Synairgen’s approach is its strategic partnership, such as that with Pharmaxis Ltd., which allows it to expand its research and development capabilities, particularly in the domain of LOXL2 inhibitors for treating idiopathic pulmonary fibrosis (IPF).
Products and Services
The company is engaged in the development of several pioneering treatments, each targeting different aspects of respiratory diseases:
- SNG001 (Inhaled interferon beta for COVID-19): This is a novel formulation designed for the treatment of COVID-19. Utilizing inhaled interferon beta, SNG001 aims to provide a direct antiviral response within the lungs, potentially mitigating the severity of the virus in infected individuals.
- Inhaled Interferon Beta for Asthma: Currently in Phase-II clinical trials, this treatment is aimed at asthma exacerbated by the common cold and flu. The inhaled delivery mechanism targets the respiratory tract directly, offering a focused approach in treating asthma triggers.
- Inhaled Interferon Beta for COPD: Also in Phase-II trials, this therapy is focused on treating or preventing Chronic Obstructive Pulmonary Disease (COPD). Similar to its application in asthma, the inhaled interferon beta intends to directly address the inflammatory processes within the lungs associated with COPD.
- LOXL2 Inhibitor for IPF: This investigational treatment is under development in collaboration with Pharmaxis Ltd. It targets the LOXL2 enzyme, which plays a significant role in the tissue remodeling associated with idiopathic pulmonary fibrosis, a chronic and often fatal lung disease.
